论文信息 - Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib. - 字舞流文

Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib.

Y. Ichinose | G. Toyokawa | Tsukihisa Yoshida | M. Yamaguchi | T. Seto | M. Takenoyama | Eiko Inamasu | F. Hirai | T. Takenaka | K. Nosaki

[1] Hiroshi Sakamoto,et al. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance. , 2014, Cancer letters.

[2] D. Hsiang,et al. Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3] Makoto Nishio,et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. , 2014, Cancer discovery.

[4] William H. Bisson,et al. Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors , 2012, Molecular Cancer Research.

[5] R. Doebele,et al. Treating ALK-positive lung cancer—early successes and future challenges , 2012, Nature Reviews Clinical Oncology.

[6] T. Clackson,et al. Crizotinib-Resistant Mutants of EML4-ALK Identified Through an Accelerated Mutagenesis Screen , 2011, Chemical biology & drug design.

[7] Hiroshi Sakamoto,et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. , 2011, Cancer cell.

[8] Young Lim Choi,et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. , 2010, The New England journal of medicine.